scholarly journals Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases

2021 ◽  
Vol 22 ◽  
pp. 101075
Author(s):  
Carolina A. Chiou ◽  
Edith R. Reshef ◽  
Suzanne K. Freitag
2021 ◽  
pp. 112067212199104
Author(s):  
Catherine J Hwang ◽  
Erin E Nichols ◽  
Brian H Chon ◽  
Julian D Perry

Thyroid eye disease is an auto-immune mediated orbitopathy which can cause dysthyroid compressive optic neuropathy. Traditional management of active thyroid eye disease includes temporizing high-dose steroids, orbital radiation and surgical decompression, which each possess significant limitations and/or side effects. Teprotumumab is an IGF-IR inhibitor recently FDA-approved for active thyroid eye disease. The authors report reversal of bilateral dysthyroid compressive optic neuropathy managed medically utilizing teprotumumab.


Author(s):  
Alison B. Callahan ◽  
Ashley A. Campbell ◽  
Susel Oropesa ◽  
Aryeh Baraban ◽  
Michael Kazim

2020 ◽  
Vol 5 (5) ◽  
pp. 804-808
Author(s):  
Tavish Nanda ◽  
Andrew Sanchez ◽  
Juhi Purswani ◽  
Cheng-Chia Wu ◽  
Michael Kazim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document